Key Information Document

BARCLAYS

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Product name	Barrier Worst-of Reverse Convertible Note Linked to a Basket of Ordinary Shares
Product identifier	ISIN: XS3520943310
PRIIP manufacturer	Barclays Bank PLC (https://derivatives.cib.barclays/). The PRIIP manufacturer is also the product issuer.
	Call +44 (0) 20 7116 9000 for more information.
Date and time of production	19 October 2026 13:41 London local time

You are about to purchase a product that is not simple and may be difficult to understand.

1. What is this product?

Type

English law governed equity-linked notes / Return depends on the performance of the underlyings / No capital protection against market risk

Objectives

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

The product is designed to provide a return in the form of (1) regular fixed interest payments and (2) either a cash payment or the delivery of the **worst performing underlying** on the **maturity date**. What you may receive will depend on the performance of the **underlyings**. The product has a fixed term and will terminate on the **maturity date**. If, at maturity, the **final reference price** of the **worst performing underlying** has fallen below its **barrier price**, the product may return shares of a value that is less than the **product notional amount** or even zero.

Interest: On each **interest payment date** you will receive an interest payment calculated by multiplying the **product notional amount** by the interest rate of 8.0129% per annum and then applying the **day count fraction** to adjust this amount to reflect the length of the relevant **interest period**. The interest payments are not linked to the performance of the **underlyings**. The relevant dates are shown in the table(s) below.

Interest payment dates
10 February 2027
10 May 2027
10 August 2027
Maturity date

Termination on the maturity date: On the **maturity date** you will receive:

1. if the **final reference price** of the **worst performing underlying** is at or above its **barrier price**, a cash payment equal to EUR 1,000; or
2. if the **final reference price** of the **worst performing underlying** is below its **barrier price**, physical delivery of the **worst performing underlying**. The number of shares of the **worst performing underlying** that will be delivered will be calculated as (i) EUR 1,000 divided by (ii) the **strike price** of such **underlying**. If this calculation would require delivery of part of a share of the relevant **underlying**, instead of receiving that part, you will be paid the cash equivalent of the value of that part (the residual cash). The value of such shares plus the residual cash will generally be less than the amount you invested.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

When purchasing this product during its lifetime, the purchase price may include accrued interest on a pro rata basis.

You do not have any entitlement to a dividend from any of the **underlyings** and you have no right to any further entitlement resulting from any such **underlying** (e.g., voting rights).

For display purposes numbers within this document have been cut off at 4 decimal places.

Underlyings	Ordinary shares of UNICREDIT SPA (UCG; ISIN: IT0005239360; Bloomberg: UCG IM Equity; RIC: CRDI.MI), COMMERZBANK AG (CBK; ISIN: DE000CBK1001; Bloomberg: CBK GY Equity; RIC: CBKG.DE), DEUTSCHE BANK AG-REGISTERED (DBK; ISIN: DE0005140008; Bloomberg: DBK GY Equity; RIC: DBKGn.DE) and BANCO BILBAO VIZCAYA ARGENTA (BBVA; ISIN: ES0113211835; Bloomberg: BBVA SQ Equity; RIC: BBVA.MC)	**Reference price**	The closing price of an **underlying** as per the relevant **reference source**
Underlying market	Equity	**Reference sources**	• UCG: Electronic Share Market • CBK: Xetra • DBK: Xetra • BBVA: Bolsa De Madrid
Product notional amount	EUR 1,000	**Final reference price**	The **reference price** on the **final valuation date**
Issue price	100% of the **product notional amount**	**Initial valuation date**	3 November 2026
Product currency	Euro (EUR)	**Final valuation date**	3 November 2027
Underlying currencies	• UCG: EUR • CBK: EUR • DBK: EUR • BBVA: EUR	**Maturity date / term**	10 November 2027
Issue date	10 November 2026	**Interest period**	Each period from, and including, an **interest payment date** (or the **issue date**, in the case of the initial **interest**

DocID: BARC20261019_1158332200 / fd25079a-9146-4fbc-879e-e590581f25cc

			period) to, but excluding, the next **interest payment date** (or the **maturity date**, in the case of the final **interest period**)
Initial reference price	The **reference price** on the **initial valuation date**	**Day count fraction**	30/360
Strike price	100% of the **initial reference price**	**Worst performing underlying**	The **underlying** with the worst performance between the **initial reference price** and the **final reference price**
Barrier price	50% of the **initial reference price**		


Intended retail investor

The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have the ability to make an informed investment decision through sufficient knowledge and understanding of the product and its specific risks and rewards, either independently or through professional advice, and they may have experience of investing in and/or holding a number of similar products providing a similar market exposure;
2. they seek income, expect the movement in the underlyings to perform in a way that generates a positive return. They have a very short investment horizon;
3. they are able to bear a total loss of their initial investment, consistent with the redemption profile of the product at maturity (market risk);
4. they accept the risk that the issuer could fail to pay or perform its obligations under the product irrespective of the redemption profile of the product (credit risk);
5. they are willing to accept a level of risk of 6 out of 7 to achieve potential returns, which reflects the second highest risk (as shown in the summary risk indicator below which takes into account both market risk and credit risk).

2. What are the risks and what could I get in return?

Risk indicator





The risk indicator assumes you keep the product for 1 year. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or may have to sell at a price that significantly impacts on how much you get back.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance of the **underlyings** at a high level and the potential for us to be unable to pay you any amounts due as very unlikely.

To the extent the currency of the country in which you purchase this product differs from the product currency, please be aware of currency risk. You will receive payments in a different currency so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Inflation erodes the purchasing value of cash over time and this may result in the decline in real terms of any capital reimbursed or interest you may be paid under the investment.

In the event of physical delivery of any of the **underlyings** on termination of the product, you may incur a loss if the value of such **underlying** decreases between termination of the product and the date on which such **underlying** is credited to your securities account.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

Investment performance information

Main factors likely to affect future returns on the product

Your return on the product at the end of the recommended holding period will principally be affected by (1) the price at which you purchase the product, (2) the performance of the **underlyings** over the recommended holding period and (3) the ability of the issuer to make payments that become due on the product. The value of the product before the **maturity date** will also be affected by general economic and market conditions, the volatility of the **underlyings** (which is a measure of the extent of movement in the prices of the **underlyings**), interest rates, the dividend yield of the **underlyings**, the correlation between the various **underlyings**, the remaining time to maturity and the ability of the issuer to make payments.

What could affect my return positively?

• The product provides a return in the form of fixed rate interest payments and, as such, there are no factors that could positively affect your return.

What could affect my return negatively?

• A decrease in the prices of the **underlyings**

• The occurrence of a barrier event

• The issuer's inability to make payments on the product when they fall due

The factors listed above provide general guidance on how changes in the prices of the **underlyings** may affect your return if you purchase the product at inception and hold it to the end of the recommended holding period. If you purchase or sell the product after inception, your return on the product will also be affected by the purchase or sale price and the prices of the **underlyings** at the time of sale or, in the case of a purchase, at and following the time of purchase. The precise impact will depend on the timing and effects of these changes, and the above list should not be viewed as guaranteeing a particular outcome. See "1. What is this product?" for a discussion of how the payments you will receive during the life of the product and what you may receive at the end of the recommended holding period will be calculated.

In severely adverse market conditions, if you hold the product to the end of the recommended holding period, you may lose your entire investment.

DocID: BARC20261019_1158332200 / fd25079a-9146-4fbc-879e-e590581f25cc

If you sell the product in severely adverse market conditions prior to the recommended holding period, your return may be lower than what you would have received if you held the product to the end of the recommended holding period and may be as low as zero. See ”5. How long should I hold it and can I take money out early” below for additional information.

3. What happens if the manufacturer is unable to pay out?

You are exposed to the risk that the issuer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

4. What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for the recommended holding period. They include potential early exit penalties. The figures assume you invest EUR 10,000. The figures are estimates and may change in the future.

Costs over time

Investment: EUR 10,000	
Scenarios	***If you cash in at the end of the recommended holding period***
Total costs	EUR 424.00
Impact on return (RIY) per year	4.7858%

The “Total costs” in the table above represents in monetary terms the aggregated amount of costs associated with the investment, assuming the product performs in line with the moderate performance scenario. The “Impact on return” represents how much the expected costs of the product would affect your return in such scenario. Disregarding the impact on your return in that scenario, the estimated entry and exit costs as a percentage of the **product notional amount** are estimated to be 4.24% if you cash in at the end of the recommended holding period.

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

The table shows the impact on return per year.			
One-off costs	*Entry costs*	4.7858%	The impact of the costs already included in the price.
	Exit costs	0%	The impact of the costs of exiting your investment when it matures.

The costs shown in the table above represent the split of the reduction in yield shown in the costs over time table at the end of the recommended holding period. The split of the actual estimated costs of the product as a percentage of the **product notional amount** is estimated to be as follows: entry costs: 4.24% and exit costs: 0%.

5. How long should I hold it and can I take money out early?

Recommended holding period: 1 year

The product aims to provide you with the return described under “1. What is this product?” above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 10 November 2027 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

Exchange listing	Not applicable	**Price quotation**	Percentage
Smallest tradable unit	EUR 1,000		

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: 1 Churchill Place, London, E14 5HP, England, UK, by email to: IBKIDComplaints@barclays.com or at the following website: https://derivatives.cib.barclays/.

7. Other relevant information

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with your bank or advisor.

The offering of this product has not been registered under the U.S. Securities Act of 1933, as amended. This product may not be offered or sold, directly or indirectly, in the United States of America or to U.S. persons. The term "U.S. person" is defined in Regulation S under the U.S. Securities Act of 1933, as amended.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are available free of charge from Barclays Bank PLC, 1 Churchill Place, London, E14 5HP, England, UK.

DocID: BARC20261019_1158332200 / fd25079a-9146-4fbc-879e-e590581f25cc